Control of disease progress in Mycobacterium avium-infected AIDS patients.
Hoffner
S E
SE
National Bacteriological Laboratory, Stockholm.
Källenius
G
G
Svenson
S B
SB
D017088:AIDS-Related Opportunistic Infections / Q000150:complications* / Q000188:drug therapy / Q000382:microbiology; D000163:Acquired Immunodeficiency Syndrome / Q000150:complications* / Q000382:microbiology; D000900:Anti-Bacterial Agents; D016207:Cytokines / Q000494:pharmacology; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D004977:Ethambutol / Q000627:therapeutic use; D015497:HIV-1 / Q000187:drug effects / Q000254:growth & development / Q000302:isolation & purification; D006801:Humans; D007375:Interleukin-1 / Q000096:biosynthesis; D008264:Macrophages / Q000378:metabolism / Q000382:microbiology; D015269:Mycobacterium avium Complex / Q000254:growth & development / Q000302:isolation & purification; D015270:Mycobacterium avium-intracellulare Infection / Q000150:complications* / Q000188:drug therapy / Q000382:microbiology
D000900:Anti-Bacterial Agents; D016207:Cytokines; D007375:Interleukin-1; D004977:Ethambutol